The impact of IdeS (imlifidase) on allo‐specific, xeno‐reactive, and protective antibodies in a sensitized rhesus macaque model

Abstract

BackgroundHighly sensitized patients face many barriers to kidney transplantation, including higher rates of antibody‐mediated rejection after HLA‐incompatible transplant. IdeS, an endopeptidase that cleaves IgG nonspecifically, has been trialed as desensitization prior to kidney transplant, and successfully cleaves donor‐specific antibody (DSA), albeit with rebound.MethodsIdeS was generated and tested (2 mg/kg, IV) in two naïve and four allosensitized nonhuman primates (NHP). Peripheral blood samples were collected at regular intervals following IdeS administration. Total IgG, total IgM, and anti‐CMV antibodies were quantified with ELISA, and donor‐specific antibody (DSA) and anti‐pig antibodies were evaluated using flow cytometric crossmatch. B cell populations were assessed using flow cytometry.ResultsIdeS successfully cleaved rhesus IgG in vitro. In allosensitized NHP, robust reduction of total, DSA, anti‐pig, and anti‐CMV IgG was observed within one day following IdeS administration. Rapid rebound of all IgG antibody populations was observed, with antibody levels returning to baseline around day 14 post‐infusion. Total IgM level was not affected by IdeS. Interestingly, a comparable reduction in antibody populations was observed after the second dose of IdeS. However, we have not observed any significant modulation of B cell subpopulations after IdeS.ConclusionsThis study evaluated efficacy of IdeS in the allosensitized NHP in IgG with various specificities, mirroring antibody kinetics in human patients. The efficacy of IdeS on preexisting anti‐pig antibodies may be useful in clinical xenotransplantation. However, given the limitation of IdeS on its durability as a monotherapy, optimization of IdeS with other agents targeting the humoral response is further needed.

Imlifidase for hematologists: Creating a therapeutic window in the presence of neutralizing alloantibodies

“…Imlifidase has a unique specificity for IgG and cleaves IgG in the heavy chains, which generates one F(ab՛)2 and two monomeric Fc fragments 3 (Figure 1). This leads to a rapid degradation of all circulating IgG within 6 h, with antibody levels returning to baseline around Day 14 postinfusion 4 . Imlifidase itself will be cleared from the circulation within 24 h. The theoretical concept for imlifidase is that antibody‐driven disorders could temporarily be mitigated.…”